Drugs Similar to Tianeptine for Melancholic Depression with Anhedonia

Understanding Why Tianeptine is Different

1. Mu-opioid receptor (MOR) agonism - the primary mechanism behind its rapid mood-lifting and anti-anhedonic effects
2. AMPA/glutamate receptor modulation - increases AMPA receptor throughput, similar to how ketamine works downstream
3. Dopamine modulation in the nucleus accumbens - increases NAcc extracellular dopamine and dopamine turnover (Kaplan & Sadock's Comprehensive Textbook)

1. Opioid Pathway (Closest Mechanism Match)

Buprenorphine (low dose)

• Partial mu-opioid agonist + kappa-opioid antagonist (KOR antagonism is pro-reward)
• Marketed as Brixelle in some countries specifically for MDD; studied at 0.1-2 mg/day
• The KOR antagonism dimension is arguably better for anhedonia than tianeptine's pure MOR agonism
• FDA approved (in combination with samidorphan) as Auvelity component; pure form off-label for depression
• Significant abuse risk is lower than tianeptine at therapeutic doses

Buprenorphine + Samidorphan (Auvelity - adjunctive)

• The samidorphan attenuates MOR-mediated abuse potential while preserving antidepressant effect
• Phase III trials showed significant improvement in MDD; approved as adjunctive treatment

2. Glutamate/NMDA Pathway (Closest Mechanistic Overlap with Tianeptine's AMPA Effects)

Esketamine (Spravato)

• NMDA antagonist that rapidly increases synaptic glutamate/AMPA throughput - the same downstream pathway tianeptine modulates
• FDA approved as of January 2025 as monotherapy for treatment-resistant depression
• Fastest acting agent for anhedonia; studies show improvement in SHAPS (anhedonia scale) scores within 40 minutes of infusion, lasting up to 3 days (PMC11930767)
• Neural changes in hippocampus and dACC specific to anhedonia, persisting after controlling for global depression
• Clinic-administered (intranasal), not for home use

Ketamine infusions (IV)

• Same mechanism as esketamine; evidence shows mesolimbic dopamine activation (PMID 36516891) - overlapping with tianeptine's dopamine effects
• Targets the same reward circuitry deficits in melancholic depression
• Off-label but widely available at ketamine clinics

Axsome's AXS-05 (dextromethorphan/bupropion - Auvelity)

• Oral NMDA antagonist (dextromethorphan) + NDRI (bupropion) combination
• FDA approved for MDD in 2022; acts faster than standard antidepressants
• The NMDA component overlaps with tianeptine's glutamate mechanism

3. Dopamine Pathway (Best for Anhedonia Specifically)

Bupropion (Wellbutrin)

• Dopamine + norepinephrine reuptake inhibitor (NDRI) - directly targets the hypodopaminergia underlying anhedonia
• Evidence shows it outperforms SSRIs for anhedonia specifically, with effects becoming more pronounced at higher doses (Phase 2 studies)
• Minimal emotional blunting (unlike SSRIs)
• First-line for melancholic depression with motivational anhedonia and low energy
• Kaplan & Sadock's lists it as having "effect on anhedonia and minimal sexual side effects"

Cariprazine (Vraylar)

• D3 > D2 partial agonist; D3 receptors are densely expressed in the reward/motivation circuit
• FDA approved as adjunctive antidepressant; the D3 agonism is specifically targeted at negative symptoms and anhedonia
• Better for motivational anhedonia than hedonic anhedonia

Pramipexole

• D3/D2 agonist; off-label but substantial evidence base for bipolar depression and treatment-resistant melancholic depression
• Directly mimics dopamine in reward circuitry; often used when anhedonia is the dominant residual symptom

4. Multimodal / Atypical Agents

Agomelatine (Valdoxan)

• Melatonin MT1/MT2 agonist + 5-HT2C antagonist
• 5-HT2C antagonism disinhibits dopamine and norepinephrine release in the prefrontal cortex - an indirect pro-dopaminergic effect similar to tianeptine's NAcc dopamine effects
• Good evidence for melancholic features; dose range 25-50 mg/night
• Not available in the US but widely used in Europe, Australia, and elsewhere
• Liver monitoring required

Vortioxetine (Trintellix)

• Multimodal: SERT inhibitor + 5-HT3/7 antagonist + 5-HT1A partial agonist
• Has been studied for anhedonia in MDD specifically; has pro-cognitive and pro-dopaminergic downstream effects
• Better than SSRIs for anhedonia but not as direct as bupropion or opioid-pathway agents

Mirtazapine

• NaSSA; strong for melancholic features particularly with prominent sleep disruption, weight loss, and psychomotor retardation
• Alpha-2 antagonism increases norepinephrine and dopamine release
• Kaplan & Sadock's specifically notes superior efficacy in melancholic depression with dual serotonin/noradrenaline action

5. TCAs - The Older Melancholic Benchmark

Nortriptyline / Imipramine

• Historically the reference standard for melancholic depression; studies show TCAs outperform SSRIs specifically in the melancholic subtype
• Strong norepinephrine reuptake inhibition + some dopamine effects
• Kaplan & Sadock's Synopsis: "Antidepressants with dual action on both serotonergic and noradrenergic receptors may have greater efficacy in melancholic depressions"
• Side effect burden limits use but efficacy for melancholic features is high

Summary Table

Practical Notes

• KOR antagonism (kappa-opioid) is now considered a key anti-anhedonic mechanism - aticaprant (J&J's KOR antagonist) showed promise in Phase 3 for anhedonic depression but failed in 2025; navacaprant (Neumora) also failed. This area remains active despite setbacks.
• SSRIs should not be first-line for anhedonia - evidence consistently shows they can worsen emotional blunting and leave anhedonia as residual symptoms
• For melancholic subtype specifically, the evidence favors: TCAs > SNRIs/agomelatine > SSRIs in terms of subtype match
• For anhedonia as the primary target: ketamine/esketamine > bupropion > cariprazine/pramipexole > opioid-pathway agents

Disclaimer: This is for informational purposes. Drug selection for depression should always involve a prescribing clinician, particularly given the abuse potential of opioid-mechanism drugs and the monitoring requirements for some agents listed here.